Sichuan Baili Pharmaceutical Co., Ltd. clinical trials

A subsidiary of Sichuan Biokin Pharmaceutical Co., Ltd.

The registry lists 140 studies whose lead sponsor is Sichuan Baili Pharmaceutical Co., Ltd.. 98 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 23, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 140. List all 140 → · All Sichuan Biokin Pharmaceutical Co., Ltd. studies →

• A Study of BL-M07D1 in Patients With Recurrent or Metastatic Gynecologic MalignanciesRecruitingNCT06131450Phase 1/2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-M08D in Patients With Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid TumorsRecruitingNCT07780318Phase 1/2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid TumorsRecruitingNCT07763639Phase 1

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-B01D1 Plus an Anti-PD-1 Antibody Versus Nab-paclitaxel Plus an Anti-PD-1 Antibody in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (PANKU-Breast04)RecruitingNCT07729956Phase 3

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-M08D in Patients With Locally Advanced or Metastatic Melanoma and Other Solid TumorsNot yet recruitingNCT07841925Phase 1/2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma and Other Solid TumorsNot yet recruitingNCT07837622Phase 2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsRecruitingNCT07763652Phase 1

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07827261Phase 2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal CarcinomaNot yet recruitingNCT07797881Phase 2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of Anti-PD-1 Antibody With or Without BL-B01D1 as Maintenance Therapy Following Anti-PD-1 Antibody Plus Chemotherapy for the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (PANKU-NPC02)Not yet recruitingNCT07783321Phase 3

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study Comparing BL-M07D1 With DS-8201 in Patients With HR-Positive, HER2-Low Expressing Recurrent/Metastatic Breast CancerRecruitingNCT07678957Phase 2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell LymphomaNot yet recruitingNCT07818499Phase 1/2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid TumorsNot yet recruitingNCT07818486Phase 1/2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid LeukemiaRecruitingNCT07255872Phase 2/3

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)RecruitingNCT07640789Phase 3

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsRecruitingNCT07753226Phase 1

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid TumorsRecruitingNCT07678970Phase 1

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-M08D1 in Patients With Recurrent or Metastatic Gynecological Malignancies and Other Solid TumorsNot yet recruitingNCT07793825Phase 1/2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid TumorRecruitingNCT05194982Phase 1

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid TumorRecruitingNCT05262491Phase 1

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaRecruitingNCT05623982Phase 1/2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid TumorsRecruitingNCT05470348Phase 1

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid TumorsRecruitingNCT05461768Phase 1

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System TumorsRecruitingNCT05785039Phase 2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid TumorsRecruitingNCT04794972Phase 1

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung CancerRecruitingNCT05924841Phase 2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological MalignanciesRecruitingNCT06066203Phase 1/2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid TumorsRecruitingNCT05631964Phase 1

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-M11D1 in Patients With Relapsed/Refractory Myelodysplastic SyndromesNot yet recruitingNCT07591168Phase 1/2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-ARC002 in Patients With Locally Advanced or Metastatic Solid TumorsRecruitingNCT07591155Phase 1

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study Comparing BL-M07D1 With Physician's Choice Therapy in Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Failed Prior Treatment With Oxaliplatin, Fluorouracil and IrinotecanNot yet recruitingNCT07730489Phase 3

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsNot yet recruitingNCT07788950Phase 2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast CancerRecruitingNCT06891833Phase 2/3

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05)Not yet recruitingNCT07739199Phase 2/3

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study Evaluating BL-B01D1 in Combination With a PD-1/VEGF Bispecific Antibody Versus Tislelizumab Plus Platinum-doublet Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer(PANKU-Lung06)Not yet recruitingNCT07739186Phase 2/3

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of SI-B036 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid TumorsNot yet recruitingNCT07744243Phase 1

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Gynecological Malignancies and Other Solid TumorsNot yet recruitingNCT07769229Phase 2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gynecological Tumors and Other Solid TumorsNot yet recruitingNCT07778862Phase 1

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung CancerRecruitingNCT07654400Phase 2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)RecruitingNCT07642024Phase 2/3

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07)RecruitingNCT07502300Phase 3

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy FailureRecruitingNCT07606599Phase 3

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy(PANKU-BTC01)RecruitingNCT07582315Phase 3

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial CarcinomaRecruitingNCT06405425Phase 2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid TumorsRecruitingNCT06437522Phase 2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid TumorsRecruitingNCT06475300Phase 2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung CancerRecruitingNCT06437509Phase 2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast CancerRecruitingNCT06471205Phase 2

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate CancerNot yet recruitingNCT07641855Phase 2/3

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.

• A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03)RecruitingNCT07648914Phase 3

  Sponsor listed in the registry: Sichuan Baili Pharmaceutical Co., Ltd.